Cerveau Technologies, Inc. and Enigma Biomedical Group, Inc., sign agreement with CAMH

(Centre for Addiction and Mental Health) Cerveau Technologies, Inc. and Enigma Biomedical Group, Inc., today announced an agreement with the Centre for Addiction and Mental Health (CAMH) in Toronto, Ontario to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain.